[3] Reed, J., Bain, S., &Kanamarlapudi, V
Shop All Find Your Perfect Supergut Routine Take our quick wellness quiz and discover the personalized path to better gut health and sustainable results
A meta-analysis of these studies revealed a statistically non-significant decrease in IMT with a mean change from baseline of 0.06 [0.15, 0.03] mm
In the SUSTAIN clinical trial program evaluating subcutaneous semaglutide for type 2 diabetes, once-weekly dosing (0.5 mg or 1.0 mg) reduced HbA1c by 1.5% to 1.8% from baseline, with superior glycemic control compared to specific comparators in head-to-head trials (SUSTAIN-7 vs dulaglutide
Currently, there is no evidence to support using GLP-1 agonists as a primary replacement for standard immunosuppressive therapy
Unlike Ozempic, which works through GLP-1 alone, retatrutide adds GIP and glucagon receptor activity on top of the GLP-1 backbone